Bisoprolol Hemifumarate + Hydrochlorothiazide

Name	Bisoprolol Hemifumarate + Hydrochlorothiazide
Classes	Cardiovascular Agent Antihypertensive Antihypertensive Combination
Diseases	Cardiovascular Disease Hypertension (High Blood Pressure)

Back

Bangla

English

Bisoprolol Hemifumarate + Hydrochlorothiazide

Bisoprolol Hemifumarate + Hydrochlorothiazide is a combination medication that works by two mechanisms to reduce blood pressure and improve cardiovascular function.

Bisoprolol hemifumarate is a beta-blocker that works by blocking the effects of adrenaline and noradrenaline, on the heart and blood vessels. This results in a slower heart rate and decreased cardiac output, leading to reduced blood pressure.

Hydrochlorothiazide is a diuretic that works by increasing the production of urine. This helps the body get rid of excess salt and water, which reduces blood volume and pressure

Indication and Usage

Bisoprolol Hemifumarate + Hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).

Hypertension (High Blood Pressure)

Dosage & Administration (How to take this medication)

Bisoprolol Hemifumarate + Hydrochlorothiazide is available in tablet form.
The recommended starting dose is 5 mg bisoprolol hemifumarate and 6.25 mg hydrochlorothiazide once daily, taken orally with or without food.
In clinical trials of bisoprolol/hydrochlorothiazide combination therapy using bisoprolol doses of 2.5 to 20 mg and hydrochlorothiazide doses of 6.25 to 25 mg, the antihypertensive effects increased with increasing doses of either component.
Dosage may be adjusted based on individual response and blood pressure goals.
Take the medication at the same time each day as prescribed.

Side effect

Precaution/Good to know

In general, beta-blocking agents should be avoided in patients with overt congestive failure. However, in some patients with compensated cardiac failure, it may be necessary to utilize these agents. In such situations, they must be used cautiously.
Continued depression of the myocardium with beta-blockers can, in some patients, precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of Bisoprolol Hemifumarate + Hydrochlorothiazide should be considered. In some cases Bisoprolol Hemifumarate + Hydrochlorothiazide therapy can be continued while heart failure is treated with other drugs.
Exacerbations of angina pectoris and, in some instances, myocardial infarction or ventricular arrhythmia, have been observed in patients with coronary artery disease following abrupt cessation of therapy with beta-blockers. Such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician’s advice.
Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals.
PATIENTS WITH BRONCHOSPASTIC PULMONARY DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of the relative beta1-selectivity of bisoprolol fumarate, Bisoprolol Hemifumarate + Hydrochlorothiazide may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. Since beta1-selectivity is not absolute, the lowest possible dose of Bisoprolol Hemifumarate + Hydrochlorothiazide should be used. A beta2 agonist (bronchodilator) should be made available.
Bisoprolol Hemifumarate + Hydrochlorothiazide may cause changes in electrolyte levels, especially in individuals with liver or kidney disease. Contact your healthcare provider if you experience symptoms such as muscle weakness, cramps, or an irregular heartbeat.